Jason Chia-Hsun Hsieh1, Hung-Ming Wang1, Min-Hsien Wu1,2,3, Kai-Ping Chang4, Pei-Hung Chang5,6, Chun-Ta Liao4, Chi-Ting Liau1. 1. Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou and Chang Gung University, Taoyuan, Taiwan. 2. Graduate Institute of Biomedical Engineering, Chang Gung University, Taoyuan, Taiwan. 3. Department of Chemical Engineering, Ming Chi University of Technology, New Taipei City, Taiwan. 4. Department of Otorhinolaryngology, Head and Neck Surgery, Chang Gung Memorial Hospital and Chang Gung University, Taoyuan, Taiwan. 5. Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan and Chang Gung University, Taoyuan, Taiwan. 6. Cancer Center, Chang Gung Memorial Hospital, Keelung, and Chang Gung University, Taoyuan, Taiwan.
Abstract
BACKGROUND: Biomarkers in head and neck squamous cell carcinoma (HNSCC) emerge rapidly in recent years, especially for new targeted therapies and immunotherapies. METHODS: Recent, relevant peer-reviewed evidence were critically reviewed and summarized. RESULTS: This review article briefly introduces essential biomarker concepts, including purposes and classifications (predictive, prognostic, and diagnostic markers), and the phases of biomarker development. We summarize current biomarkers in order of clinical utility; p16 and human papillomavirus status remain the most important and validated biomarkers in HNSCC. The rationale for biomarker study design continues to evolve with technological advances, especially whole-exome or whole-genomic sequencing. Noninvasive body fluid and liquid biopsy biomarkers appear to hold strong potential for development as tools for early cancer detection, cancer diagnosis, monitoring of disease recurrence, and outcome prediction. In light of discrepancies among different technologies, standardized approaches are needed. CONCLUSION: Biomarkers from cancer tissue or blood in HNSCC could direct new anticancer therapies.
BACKGROUND: Biomarkers in head and neck squamous cell carcinoma (HNSCC) emerge rapidly in recent years, especially for new targeted therapies and immunotherapies. METHODS: Recent, relevant peer-reviewed evidence were critically reviewed and summarized. RESULTS: This review article briefly introduces essential biomarker concepts, including purposes and classifications (predictive, prognostic, and diagnostic markers), and the phases of biomarker development. We summarize current biomarkers in order of clinical utility; p16 and human papillomavirus status remain the most important and validated biomarkers in HNSCC. The rationale for biomarker study design continues to evolve with technological advances, especially whole-exome or whole-genomic sequencing. Noninvasive body fluid and liquid biopsy biomarkers appear to hold strong potential for development as tools for early cancer detection, cancer diagnosis, monitoring of disease recurrence, and outcome prediction. In light of discrepancies among different technologies, standardized approaches are needed. CONCLUSION: Biomarkers from cancer tissue or blood in HNSCC could direct new anticancer therapies.
Authors: Clemens P Spielvogel; Stefan Stoiber; Laszlo Papp; Denis Krajnc; Marko Grahovac; Elisabeth Gurnhofer; Karolina Trachtova; Vojtech Bystry; Asha Leisser; Bernhard Jank; Julia Schnoell; Lorenz Kadletz; Gregor Heiduschka; Thomas Beyer; Marcus Hacker; Lukas Kenner; Alexander R Haug Journal: Eur J Nucl Med Mol Imaging Date: 2022-09-26 Impact factor: 10.057
Authors: Susanne Flach; Karen Howarth; Sophie Hackinger; Christodoulos Pipinikas; Pete Ellis; Kirsten McLay; Giovanni Marsico; Tim Forshew; Christoph Walz; Christoph A Reichel; Olivier Gires; Martin Canis; Philipp Baumeister Journal: Br J Cancer Date: 2022-02-07 Impact factor: 9.075
Authors: Neil D Christensen; Kun-Ming Chen; Jiafen Hu; Douglas B Stairs; Yuan-Wan Sun; Cesar Aliaga; Karla K Balogh; Hannah Atkins; Debra Shearer; Jingwei Li; Sarah A Brendle; Krishne Gowda; Shantu Amin; Vonn Walter; Raphael Viscidi; Karam El-Bayoumy Journal: Chem Biol Interact Date: 2020-11-10 Impact factor: 5.168